Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS (TUDCA-ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03800524

Recruitment Status : Active, not recruiting

First Posted : January 11, 2019

Last Update Posted : July 10, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

University of Ulm

University of Sheffield

University Hospital, Tours

KU Leuven

UMC Utrecht

University of Dublin, Trinity College

Bruschettini S.r.l.

Istituto Superiore di Sanità

Motor Neurone Disease Association

European Commission

Information provided by (Responsible Party):

Humanitas Mirasole SpA

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	December 31, 2023
Estimated Study Completion Date :	December 31, 2023

Publications:

Albanese A, Ludolph AC, McDermott CJ, Corcia P, Van Damme P, Van den Berg LH, Hardiman O, Rinaldi G, Vanacore N, Dickie B; TUDCA-ALS Study Group. Tauroursodeoxycholic acid in patients with amyotrophic lateral sclerosis: The TUDCA-ALS trial protocol. Front Neurol. 2022 Sep 27;13:1009113. doi: 10.3389/fneur.2022.1009113. eCollection 2022.

To Top